Care Delivery | Provider Strategies | Investing
Biotech Investment Strategy | Buy Side and M&A
Community Health | Innovation In Flight
First In Class Hospital Venture Investing | Lessons Learned
Institutional Investor LP Perspective | VC/PE, What is Working, What Needs to Change
Patient Engagement | Creating the Connection
Public Investor Perspectives in Biotech
Silver Tsunami | Unprecedented, Unaffordable, Unceasing
Upending the US Care Model and Impact on AMCs | Planning for excellence after the cuts
Why China Biotech Is Getting a DeepSeek Moment, Too
Clinical | Technology Reaching Patients
Antimicrobial Resistance | The Urgent Global Response
Beyond Opioids: Existing Therapies and Innovations in Pain Management
Breakthroughs in Disability Technology: From Concept to Impact
Cancer’s Newest Treatments | Early Detection, Early Treatment, Rapid Therapeutic Development
Clinical Diagnoses | New Technologies, New Care Paths
Gene Editing: Precision medicine in Practice
Patient Centered Cancer Care
Rare Disease: Strategies to Maximize Patient Impact
Surgery | Regenerative and Robotic
Xenotransplant | The Clinical Reality Emerges
Digital/AI
AI at the Bedside | Is A Physician Co-Pilot Imminent?
AI Diagnostics | Is the Future of Diagnostics Moving “In Silico”?
AI Enabled Learning Health System | Can AI Finally Enable Us to Learn from Every Patient?
AI and Imaging | Radiology Led Much of the AI Revolution, How is it Being Transformed?
Cybersecurity, Privacy and Resilience in AI Age | Pitfalls to Avoid and Opportunities Ahead
KOL Deep Dive | Emerging Therapeutics
Cardiovascular Therapies | Pharmaceutical Pipeline
Dementia/AD | AD Biomarkers, Therapeutics, GLP-1 RA
Emerging Treatments for Fibrotic Disorders | Momentum Building
Emerging Treatments | Hematology and Hematological Cancers
Immunology: Creating the Next I&I Blockbuster
Neurology Therapeutic Development | Spring Has Arrived | MS, PD, ALS, Pain, Rare Diseases
Obesity and Metabolic Disorders | Mapping Medicine’s New Chapter
Oncology | Bispecifics, T-cell engagers and Combination Therapies
Ophthalmological Therapeutics | Seeing the New Era
State of Lung Cancer and Checkpoint Inhibition | Beyond PD-1/L-1, CTLA-4
